Jinfukang Oral Liquid Combined With Chemotherapy for Treating Driver Gene-negative Advanced NSCLC

Inclusion Criteria: 1. 18-80 years of age; 2. Patients with stage ⅢB-IV NSCLC are diagnosed by histopathology and cytology; 3. Patients' tumor tissues are unresectable as assessed by the investigator; 4. Have measurable disease based on RECIST 1.1; 5. Driver gene (EGFR/ALK/ROS1) is negative; 6. Patients who are receiving first-line platinum-doublet chemotherapy with remaining no fewer than 4 therapeutic cycles; 7. Patients in chemotherapy who combined with other systemic therapy (including but not limited to immune checkpoint inhibitors and anti-vascular targeted drugs) are not suitable, but with radiotherapy can be permitted; 8. During chemotherapy cycles, patients who take prior treatment with anticancer Chinese medicine less than 4 weeks can be enrolled after stopping medication. If administration time is longer than 4 weeks, at least 4 weeks washout period should be performed; 9. Patients are diagnosed with Qi-yin deficiency by the Syndrome Differentiation of Traditional Chinese Medicine; 10. The expected survival time ≥3 months; 11. The subjects volunteer to sign the informed consent. Exclusion Criteria: 1. Allergy or hypersensitivity to ingredients of the study treatment formulation; 2. Pregnant or lactating women; 3. Patients with multiple brain metastases, multiple bone metastases and liver metastases, which have great influence on survival times； 4. Patients are enrolling in other therapeutic trials; 5. The investigator does not consider the participant to be eligible for this study.